Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company reported better-than-expected performance driven by the peak season for formulations in Q1 2025, while continuing to advance the construction of the Hengning base to strengthen its integrated strategy of intermediates, active ingredients, and formulations [1][6] Financial Performance Summary - In 2024, the company achieved total revenue of 39.08 billion yuan, a year-on-year decrease of 11.2%, and a net profit attributable to the parent company of 1.81 billion yuan, down 61.7% year-on-year [5][6] - For Q1 2025, the company reported revenue of 12.64 billion yuan, a year-on-year increase of 10.2%, and a net profit of 1.05 billion yuan, up 16% year-on-year [6] - The company plans to distribute a cash dividend of 5 yuan per 10 shares, representing 93.7% of the net profit attributable to the parent company [6] Revenue and Profit Forecast - Projected total revenue for 2025 is 44.52 billion yuan, with a year-on-year growth rate of 13.9% [5] - The forecasted net profit for 2025 is 3.65 billion yuan, reflecting a significant increase of 101.3% compared to 2024 [5][6] - The company expects to gradually reduce losses from the Hengning base in 2025, with new investments supporting future growth [6] Market and Product Insights - The company's pesticide business saw a sales volume of 56,600 tons in 2024, with a revenue of 38.08 billion yuan, despite a year-on-year price decline of 14% [6] - In Q1 2025, the pesticide business achieved a sales volume of 17,200 tons, with revenue of 12.31 billion yuan, indicating a recovery in demand [6] - The report highlights that the formulation business is expected to contribute nearly half of the company's revenue during the peak sales season in H1 2025 [6]